Colgate-Palmolive Company $CL Shares Sold by Strategic Blueprint LLC

Strategic Blueprint LLC lowered its stake in shares of Colgate-Palmolive Company (NYSE:CL) by 45.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,992 shares of the company’s stock after selling 5,924 shares during the quarter. Strategic Blueprint LLC’s holdings in Colgate-Palmolive were worth $553,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of CL. Brighton Jones LLC increased its holdings in shares of Colgate-Palmolive by 4.4% during the fourth quarter. Brighton Jones LLC now owns 10,578 shares of the company’s stock valued at $962,000 after acquiring an additional 450 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Colgate-Palmolive by 76.3% during the first quarter. Woodline Partners LP now owns 46,361 shares of the company’s stock valued at $4,344,000 after acquiring an additional 20,062 shares in the last quarter. Schnieders Capital Management LLC. increased its holdings in shares of Colgate-Palmolive by 2.0% during the second quarter. Schnieders Capital Management LLC. now owns 12,494 shares of the company’s stock valued at $1,136,000 after acquiring an additional 245 shares in the last quarter. Nebula Research & Development LLC increased its holdings in shares of Colgate-Palmolive by 165.5% during the second quarter. Nebula Research & Development LLC now owns 10,326 shares of the company’s stock valued at $939,000 after acquiring an additional 6,437 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in shares of Colgate-Palmolive by 21.7% during the second quarter. Sei Investments Co. now owns 657,093 shares of the company’s stock valued at $59,732,000 after acquiring an additional 116,968 shares in the last quarter. Institutional investors and hedge funds own 80.41% of the company’s stock.

Insider Buying and Selling

In other Colgate-Palmolive news, insider John Hazlin sold 20,989 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $94.25, for a total value of $1,978,213.25. Following the sale, the insider owned 17,645 shares in the company, valued at approximately $1,663,041.25. This represents a 54.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Panagiotis Tsourapas sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $97.81, for a total value of $1,467,150.00. Following the completion of the sale, the chief operating officer owned 10,415 shares in the company, valued at approximately $1,018,691.15. This represents a 59.02% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 184,683 shares of company stock worth $17,486,693. 0.43% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CL has been the topic of several recent analyst reports. TD Cowen restated a “hold” rating and set a $85.00 price objective on shares of Colgate-Palmolive in a report on Tuesday, March 31st. Wall Street Zen downgraded shares of Colgate-Palmolive from a “buy” rating to a “hold” rating in a report on Sunday, March 29th. Rothschild & Co Redburn set a $100.00 price target on shares of Colgate-Palmolive and gave the stock a “buy” rating in a report on Tuesday, April 21st. UBS Group cut their price target on shares of Colgate-Palmolive from $100.00 to $98.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $100.00 price target on shares of Colgate-Palmolive in a report on Friday, February 20th. Twelve investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $95.56.

Colgate-Palmolive Price Performance

Shares of NYSE:CL opened at $85.40 on Friday. Colgate-Palmolive Company has a twelve month low of $74.54 and a twelve month high of $99.33. The company’s 50 day moving average is $87.95 and its 200 day moving average is $84.06. The company has a current ratio of 0.83, a quick ratio of 0.54 and a debt-to-equity ratio of 18.82. The company has a market cap of $68.51 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 4.32 and a beta of 0.34.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings data on Friday, January 30th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.91 by $0.04. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.13 billion. During the same quarter in the prior year, the firm posted $0.91 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. On average, sell-side analysts forecast that Colgate-Palmolive Company will post 3.85 EPS for the current year.

Colgate-Palmolive Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 2.5%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.52. Colgate-Palmolive’s payout ratio is currently 80.92%.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.